Skip to main content

Table 4 The Cox proportional hazards model of cancer specific survivalin synchronous and metachronous mRCC group

From: Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis

 

Synchronous mRCC (N = 144 / EVENT = 123)

Metachronous mRCC (N = 70 / EVENT = 59)

Univariable

Multivariable

Univariable

Multivariable

Hazard ratio

(95% CI)

P-value

Hazard ratio

(95% CI)

P-value

Hazard ratio

(95% CI)

P-value

Hazard ratio

(95% CI)

P-value

Risk group

Intermediate

1

   

1

 

1

 

poor

2.377 (1.591–3.553)

<.0001

  

3.536 (1.332–9.390)

0.0113

3.536 (1.332–9.390)

0.0113

Therapy

IT

1

   

1

   

TT

0.854 (0.590–1.237)

0.4041

  

0.725 (0.428–1.228)

0.2312

  

Treatment Free interval

≥1 yr

1

   

1

   

< 1 yr

1.465 (0.714–3.009)

0.2978

  

1.918 (1.089–3.378)

0.0241

  

Gender

Male

1

   

1

   

Female

1.185 (0.758–1.854)

0.4557

  

1.313 (0.768–2.246)

0.3200

  

Age (year)

 

1.002 (0.985–1.019)

0.8225

  

0.986 (0.959–1.013)

0.3126

  

Anemia

Normal

1

   

1

   

Hb < 13.5(male)/12.0(Female)

1.555 (0.977–2.475)

0.0626

  

0.738 (0.372–1.464)

0.3841

  

Hypercalcemia

Normal

1

 

1

 

1

   

> 10 mg/dL or 2.5 mmol/L

2.118 (1.297–3.460)

0.0027

2.164 (1.307–3.584)

0.0027

0.948 (0.429–2.098)

0.8956

  

Neutrophilia

Normal

1

 

1

 

1

   

< 1500 or > 7500

2.595 (1.589–4.238)

0.0001

2.655 (1.601–4.405)

0.0002

1.296 (0.631–2.661)

0.4798

  

Elevated LDH

Normal

1

   

1

   

1.5 X ULN

1.482 (0.943–2.329)

0.0883

  

1.491 (0.661–3.365)

0.3357

  

KPS

>  80

1

       

≤ 80

1.185 (0.375–3.742)

0.7730

      

Thrombocytosis

Normal

1

   

1

   

> 400 K

2.494 (1.437–4.327)

0.0012

  

1.941 (0.592–6.363)

0.2734

  
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us